Abiologics, the Flagship Pioneering startup, said it has used artificial intelligence to design proteins built from mirror-image amino acid components, a strategy intended to increase durability and potentially improve drug stability. The mirror-image design concept targets how proteins interact with biological systems, with the aim of extending functional lifespan in vivo. The company’s approach indicates a broader push toward modality-level differentiation, where AI not only proposes targets but also optimizes biochemical properties through non-standard protein architectures. Mirror-image proteins, often called D-amino acid or enantiomeric designs depending on the context, can reduce susceptibility to degradation by common biological proteases. Abiologics’ announcement is part of an innovation wave in which platform companies seek to expand protein engineering beyond traditional antibodies and recombinant therapeutics, using AI to drive faster design cycles. While specific lead programs and clinical plans were not detailed in the provided excerpt, the immediate industry relevance is that durable proteins remain a key lever for improving dosing convenience and adherence across chronic disease areas.